Coromandel International Ltd Q1 FY27 Earnings Analysis
Published 3 Jul 2026 | Fertilizers & Agrochemicals | Market Cap: ₹58.5K Cr
Price
₹2,000
Market Cap
₹58.5K Cr
P/E Ratio
27.6
Revenue Rank
Margin Rank
Earnings Summary
- Crop Protection business expects 20%-25% revenue growth driven by new registrations, product launches (six new products), and increased active ingredient volumes, especially Mancozeb with new capacities at Dahej and Sarigam. - Coromandel expects growth driven by increased manufacturing capacities, especially in active ingredients like Mancozeb (10,000 tons capacity expansion at Dahej and 20,000 tons at Sarigam).
📊 Revenue & Sales Performance
Rank 2- Crop Protection business expects 20%-25% revenue growth driven by new registrations, product launches (six new products), and increased active ingredient volumes, especially Mancozeb with new capacities at Dahej and Sarigam. - Formulation business growth projected at 14%-20%, with niche and bio pesticide products gaining traction. - Nano DAP segment shows strong growth, with 60% volume expansion and 50% market share. - Export volumes expected to rebound after Q4 slowdown; Latin American market inventory issues seem resolved. - Fertilizer volumes normalized, with record production and expanded unique grades at 35%. - Retail business targets 30% growth by adding new stores and leveraging e-commerce and drone services. - Drone business (Dhaksha) is in early growth phase, with planned new facility and product offerings within next 6-9 months. - Overall, Coromandel aims to sustain healthy volume and revenue growth across segments with improved capacities and product portfolio.
📈 Profitability & Margins
Rank 3- Coromandel expects growth driven by increased manufacturing capacities, especially in active ingredients like Mancozeb (10,000 tons capacity expansion at Dahej and 20,000 tons at Sarigam). - Crop protection business aims for aggressive 20%-25% revenue growth with new product launches and expanded import of active ingredients. - Margin sustainability is expected, with crop protection EBITDA margins around 19%, aided by currency depreciation and export growth. - Fertilizer margins face challenges due to raw material inflation, but potential government subsidy increases and price corrections may support margin recovery. - NACL acquisition is driving synergistic growth and profitability, with expected margin improvement to 9%-10% over time. - The CDMO business is in early stages with multi-year gestation but has favorable prospects due to MNC interest. - Overall, significant investments (INR 3,000+ crores) over the last two years are expected to generate target revenues and profits in coming periods.
🏗️ Capital Expenditure Plans
Yes- Dhaksha facility expansion: Moving to a larger facility expected to be ready by May 2026, aiming to enhance drone production and execution of defense orders. - Strengthening R&D: Plan to introduce new products in the next 6-9 months to capitalize on prior investments. - Dahej plant: Expanded capacity by 10,000 tons of Mancozeb with payback less than one year; an additional 20,000-ton expansion underway at Sarigam expected by mid-2026. - Technical MAP and seaweed granulation capacities are being set up in the specialty nutrient business to generate revenue in coming years. - Fluorination chemistry investment: Planned in coming quarters to develop capabilities for CDMO space, aiming for significant contributions 2-3 years down the line without immediate large-scale investments. - New Sulphuric acid plant at Kakinada commenced in Q4 2026, supporting internal requirements and cost management.
💰 Fundraising & Capital Structure
No information- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - However, it is noted that the recently acquired NACL followed a rights issue of INR 250 crores to reduce high-cost debt. - Coromandel International has made significant investments of over INR 3,000 crores in the last two years across business segments, indicating use of internal resources or financing, but no specific new fundraising is mentioned. - The company is focusing on realizing value from current investments before making large new investments, particularly in the CDMO space. - Overall, no new debt or equity fundraising plans are disclosed in the available content.
📋 Order Book & Pipeline
No information- Dhaksha, Coromandel International's defense-related venture, is currently in a recovery mode with ongoing progress. - The first order execution for Dhaksha is expected during the current year, which will boost confidence for repeat orders across various defense segments. - The company is expanding Dhaksha’s facility to a larger location, expected to be ready by May. - Strengthening R&D efforts to introduce new products in the next 6 to 9 months to realize the value of previous investments. - The drone business has taken impairment due to long lead times in order execution, indicating some delays in order book fulfillment. - Overall, initial orders are being executed with expectations for repeat orders, but specific orderbook value or number details are not disclosed.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Coromandel International Ltd Q1 FY27 results?
- Crop Protection business expects 20%-25% revenue growth driven by new registrations, product launches (six new products), and increased active ingredient volumes, especially Mancozeb with new capacities at Dahej and Sarigam. - Coromandel expects growth driven by increased manufacturing capacities, especially in active ingredients like Mancozeb (10,000 tons capacity expansion at Dahej and 20,000 tons at Sarigam).
What is Coromandel International Ltd share price analysis?
Coromandel International Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 27.6 with a market cap of ₹58,463. Investors should review the full earnings analysis for detailed insights.
Is Coromandel International Ltd planning capital expenditure?
- Dhaksha facility expansion: Moving to a larger facility expected to be ready by May 2026, aiming to enhance drone production and execution of defense orders.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
